Who
Robert Matthew Lutz
Chief Fin. & Operating Officer
Company insider
Files Form 4 as: Chief Fin. & Operating Officer, Savara; See Remark, iBio; Chief Financial Officer, Strongbridge Biopharma.
In numbers
- Trades disclosed
- 21
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $8,619
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 27 Jan 2020
- Last trade
- 15 Jul 2026
- Last filed
- 24 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 24 Jul 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 15 Jul 2026filed 24 Jul 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 15 Jul 2026filed 24 Jul 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 15 Jul 2026filed 24 Jul 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 14 Dec 2025filed 16 Dec 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Code F | $469K67,760 at $6.92 | filing |
| 13 Feb 2025filed 14 Feb 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Code F | $108K38,263 at $2.83 | filing |
| 12 Dec 2024filed 16 Dec 2024 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 12 Dec 2024filed 16 Dec 2024 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 14 Dec 2023filed 15 Dec 2023 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 14 Dec 2023filed 15 Dec 2023 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 24 Feb 2023filed 28 Feb 2023 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 24 Feb 2023filed 28 Feb 2023 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 11 Nov 2022filed 15 Nov 2022 | IBIO iBioBiotechnology | SEC FORM 4 Code A | —100,057 at $0.00 | filing |
| 29 Aug 2022filed 31 Aug 2022 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 10 Mar 2022filed 14 Mar 2022 | IBIO iBioBiotechnology | SEC FORM 4 Sold | $8,61924,625 at $0.35 | filing |
| 23 Aug 2021filed 25 Aug 2021 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 4 Mar 2021filed 4 Mar 2021 | IBIO iBioBiotechnology | SEC FORM 4 Code A | —232,000 at $0.00 | filing |
| 4 Mar 2021filed 4 Mar 2021 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 22 Feb 2021filed 23 Feb 2021 | Strongbridge Biopharma | SEC FORM 4 Code F | $25K6,978 at $3.62 | filing |
| 7 Jan 2021filed 8 Jan 2021 | Strongbridge Biopharma | SEC FORM 4 Code A | —147,500 at $0.00 | filing |
News
Head to Head Comparison: Myriad Genetics (NASDAQ:MYGN) & iBio (NASDAQ:IBIO)IBIO · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Robert Matthew Lutz; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.